2 terminated, 1 active not recruiting, 1 recruiting. 2 Phase 1, 2 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Terminated 1 |
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
| Early Phase 1 | 1 | Terminated 1 |
Follow Refractory Lymphoblastic Lymphoma: new trials by email Literature Review of Refractory Lymphoblastic Lymphoma trials Research Report on Refractory Lymphoblastic Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia Autologous Anti-CD19/CD20/CD22 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration - Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 24 | 2026-01-14 | 2026-08-26 |
| Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Cyclophosphamide, Cytarabine, Dexamethasone - Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2022-02-17 | 2025-08-11 |
| Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia Bortezomib, Clofarabine, Cyclophosphamide - Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 42 | 2017-08-09 | 2026-08-10 |
| Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma Sirolimus - Relapsed Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma | Early Phase 1 | Terminated | Children's Hospital Medical Center, Cincinnati | 3 | 2012-08-01 | 2020-09-14 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Burkitt Lymphoma (2) · Blast Crisis (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Lymphoma, Non-Hodgkin (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Leukemia (4) · Leukemia, Lymphoid (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Lymphoma (3) · DNA Virus Infections (2) · Epstein-Barr Virus Infections (2) · Herpesviridae Infections (2) · Infections (2)
Cyclophosphamide (3) · CT-P10 (2) · Calcium Dobesilate (2) · Dexamethasone (2) · Rituximab (2) · Vincristine (2) · auricularum (2) · dexamethasone 21-phosphate (2) · dexamethasone acetate (2) · pegfilgrastim (2) · Biopsy (1) · Blood Component Removal (1) · Bortezomib (1) · Clofarabine (1) · Cytarabine (1)
M.D. Anderson Cancer Center (2) · Children's Hospital Medical Center, Cincinnati (1) · Ohio State University Comprehensive Cancer Center (1)
United States (4)
Maro Ohanian (1) · Maureen O'Brien, MD (1) · Nicholas Short, MD (1) · Sumithira Vasu, MD (1)